ITM, Navigo collaborate on radioisotope

By staff writers

December 3, 2021 -- German radiopharmaceutical firm ITM Isotope Technologies Munich and Navigo Proteins are teaming up to develop a fibroblast activation protein (FAP)-targeted radiopharmaceutical program for the treatment of solid tumors.

Navigo develops optimized scaffold protein-based affinity ligands called Affilin molecules, the companies said. Under the agreement, Navigo's protein engineering platform will be used to develop and select a FAP-targeting Affilin molecule, which will be paired with a therapeutic radioisotope provided by ITM. Following the selection, ITM will have exclusive rights to further develop the radiolabeled FAP-specific Affilin through clinical testing in potentially multiple cancer indications.

The agreement also includes a nonexclusive license for diagnostic use in radioimaging.

Copyright © 2021

To read this and get access to all of the exclusive content on create a free account or sign-in now.

Member Sign In:
MemberID or Email Address:  
Do you have a password?
No, I want a free membership.
Yes, I have a password:  
Forgot your password?
Sign in using your social networking account:
Sign in using your social networking